Unum gets a reprieve from the FDA — partial hold lifted after 9 days
The FDA has lifted the partial hold on Unum Therapeutics’ ACTR707 in combination with rituximab in patients with CD20+ B cell non-Hodgkin lymphoma.
In a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
